BRAF and melanoma: It was reported RAF inhibitors with anti-SRC activity show improved anti-proliferative activities in BRAF-mutant melanoma cells.20 To assess whether AZ304 plays a role in blocking SRC tyrosine kinase activation, the effects of single and combined treatments on SRC and STAT3 phosphorylation were examined (Fig. 4c).